LT4255563T - 5'-o-fenilacetiluridinas ir jo terapinis panaudojimas - Google Patents
5'-o-fenilacetiluridinas ir jo terapinis panaudojimasInfo
- Publication number
- LT4255563T LT4255563T LTEPPCT/US2021/061053T LTUS2021061053T LT4255563T LT 4255563 T LT4255563 T LT 4255563T LT US2021061053 T LTUS2021061053 T LT US2021061053T LT 4255563 T LT4255563 T LT 4255563T
- Authority
- LT
- Lithuania
- Prior art keywords
- phenylacetyluridine
- therapeutic use
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119764P | 2020-12-01 | 2020-12-01 | |
| PCT/US2021/061053 WO2022119784A1 (en) | 2020-12-01 | 2021-11-30 | 5'-o-phenylacetyluridine and therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT4255563T true LT4255563T (lt) | 2026-04-10 |
Family
ID=81854225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2021/061053T LT4255563T (lt) | 2020-12-01 | 2021-11-30 | 5'-o-fenilacetiluridinas ir jo terapinis panaudojimas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230416292A1 (https=) |
| EP (2) | EP4255563B1 (https=) |
| JP (1) | JP2023551467A (https=) |
| KR (1) | KR20230112118A (https=) |
| CN (1) | CN116782912A (https=) |
| AU (1) | AU2021391411A1 (https=) |
| BR (1) | BR112023010517A2 (https=) |
| CA (1) | CA3199559A1 (https=) |
| DK (1) | DK4255563T3 (https=) |
| FI (1) | FI4255563T3 (https=) |
| IL (1) | IL303100A (https=) |
| LT (1) | LT4255563T (https=) |
| MX (1) | MX2023006343A (https=) |
| PL (1) | PL4255563T3 (https=) |
| PT (1) | PT4255563T (https=) |
| WO (1) | WO2022119784A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4210709T (pt) | 2020-09-14 | 2026-02-04 | Pharma Cinq Llc | 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿ |
| TW202317144A (zh) * | 2021-06-14 | 2023-05-01 | 美商維納拓爾斯製藥公司 | 口服生物可利用的核苷類似物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0346108A3 (en) * | 1988-06-09 | 1991-04-24 | The Wellcome Foundation Limited | Anti-infective nucleosides |
| JP2526414B2 (ja) | 1994-05-20 | 1996-08-21 | 工業技術院長 | 制ガン剤エステル化合物及びその製造方法 |
| JP4408450B2 (ja) * | 1994-07-01 | 2010-02-03 | ウェルスタット セラピューティクス コーポレイション | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 |
| EP1808177B1 (en) * | 1999-02-23 | 2018-08-08 | The Regents of The University of California | Methods of treatment of mitochondrial disorders |
| SI2153870T1 (sl) * | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| PT2922576T (pt) * | 2012-11-21 | 2018-01-24 | Horizon Therapeutics Llc | Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática |
| PL3182980T3 (pl) * | 2014-08-19 | 2021-04-19 | Wellstat Therapeutics Corporation | Leczenie chorób niedoboru glikozylacji |
| AU2019215105B2 (en) * | 2018-02-01 | 2024-12-19 | Pharma Cinq, Llc | Compositions and devices for systemic delivery of uridine |
| WO2022089612A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海岸阔医药科技有限公司 | 尿苷衍生物在制备药物中的应用 |
-
2021
- 2021-11-30 US US18/036,744 patent/US20230416292A1/en active Pending
- 2021-11-30 BR BR112023010517A patent/BR112023010517A2/pt unknown
- 2021-11-30 EP EP21901291.1A patent/EP4255563B1/en active Active
- 2021-11-30 WO PCT/US2021/061053 patent/WO2022119784A1/en not_active Ceased
- 2021-11-30 KR KR1020237017758A patent/KR20230112118A/ko active Pending
- 2021-11-30 AU AU2021391411A patent/AU2021391411A1/en active Pending
- 2021-11-30 PL PL21901291.1T patent/PL4255563T3/pl unknown
- 2021-11-30 CA CA3199559A patent/CA3199559A1/en active Pending
- 2021-11-30 MX MX2023006343A patent/MX2023006343A/es unknown
- 2021-11-30 LT LTEPPCT/US2021/061053T patent/LT4255563T/lt unknown
- 2021-11-30 FI FIEP21901291.1T patent/FI4255563T3/fi active
- 2021-11-30 PT PT219012911T patent/PT4255563T/pt unknown
- 2021-11-30 EP EP25219839.5A patent/EP4711007A3/en active Pending
- 2021-11-30 DK DK21901291.1T patent/DK4255563T3/da active
- 2021-11-30 IL IL303100A patent/IL303100A/en unknown
- 2021-11-30 JP JP2023532125A patent/JP2023551467A/ja active Pending
- 2021-11-30 CN CN202180080169.0A patent/CN116782912A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL4255563T3 (pl) | 2026-04-20 |
| EP4255563B1 (en) | 2025-12-31 |
| WO2022119784A1 (en) | 2022-06-09 |
| JP2023551467A (ja) | 2023-12-08 |
| AU2021391411A1 (en) | 2023-07-20 |
| IL303100A (en) | 2023-07-01 |
| EP4711007A2 (en) | 2026-03-18 |
| PT4255563T (pt) | 2026-03-24 |
| MX2023006343A (es) | 2023-06-12 |
| CN116782912A (zh) | 2023-09-19 |
| BR112023010517A2 (pt) | 2024-02-06 |
| KR20230112118A (ko) | 2023-07-26 |
| EP4255563A1 (en) | 2023-10-11 |
| FI4255563T3 (fi) | 2026-03-13 |
| EP4711007A3 (en) | 2026-04-01 |
| AU2021391411A9 (en) | 2024-07-18 |
| CA3199559A1 (en) | 2022-06-09 |
| EP4255563A4 (en) | 2024-09-11 |
| DK4255563T3 (da) | 2026-03-16 |
| US20230416292A1 (en) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019475D0 (en) | Therapeutic compounds and their use | |
| IL304734A (en) | Therapeutic and diagnostic materials and their uses | |
| GB202108572D0 (en) | Therapeutic compounds and their use | |
| IL289167A (en) | The history of 2h-indazole and their use in the treatment of diseases | |
| IL289289A (en) | History of polyaromatic ureas and their use in the treatment of muscle diseases | |
| GB201905520D0 (en) | Compounds and their therapeutic use | |
| GB201918541D0 (en) | Therapeutic compounds and their use | |
| GB202014736D0 (en) | Novel compounds and their use in therapy | |
| LT4255563T (lt) | 5'-o-fenilacetiluridinas ir jo terapinis panaudojimas | |
| IL291543A (en) | Medical preparations and their use | |
| PL3937948T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych | |
| PL3937949T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu upośledzenia funkcji oddechowych | |
| IL319234A (en) | Pyrazolylsulfonamide compounds and their use in therapy | |
| GB202201137D0 (en) | Therapeutic and diagnostic agents and uses thereof | |
| HK40101806A (en) | 5'-o-phenylacetyluridine and therapeutic use | |
| GB202012482D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB202003057D0 (en) | Medicament and use thereof | |
| PL3797772T3 (pl) | Rebamipid do zastosowania w zapobieganiu i leczeniu choroby Leśniowskiego-Crohna | |
| GB202507606D0 (en) | Medicament and use thereof | |
| GB202318926D0 (en) | Block copolymer and therapeutic use thereof | |
| GB202110932D0 (en) | Novel compounds and their use in therapy | |
| GB2610895C (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| GB202011808D0 (en) | Novel compounds and their use in therapy | |
| GB202017850D0 (en) | GAPS-Mind the GAP-Common Gaps in medical and surgical practice | |
| GB202212240D0 (en) | New formulations and medical uses thereof |